Ainos, Inc. (AIMD)

1.0507 -0.0193 (-1.80%) 收市：04:00PM EDT

Ainos, Inc.

8880 Rio San Diego Drive
Suite 800
San Diego, CA 92108
United States
858 869 2986
https://www.ainos.com

版塊: Healthcare
行業: Medical Devices
全職員工: 46

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Chun-Hsien Tsai	Chairman of Board, President & CEO	112.12k	無	1970
Mr. Lawrence Kennedy Lin	Executive Vice President of Operations	144k	無	1969
Mr. Hsin-Liang Lee	Chief Financial Officer	無	無	1971
Mr. Chih-Heng Lu	Director of Corporate Developoment	無	無	1980

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

公司管治

截至 無 止，Ainos, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。